Straight from your article: “ It will be interesting to see if Brazil adopts both lenzilumab and leronlimab or selects one of the other. Based on the clinical trial result and the MOA leronlimab is the superior drug candidate and probably has less ties to United States pressure to keep it all for themselves.” Enough said,... Thank you!